AOD-9604 (Advanced Obesity Drug 9604) is a synthetic peptide fragment of human growth hormone (hGH176-191) that was originally developed by Monash University as an obesity treatment. It retains the fat-metabolizing properties of full hGH while eliminating the insulin-desensitizing and IGF-1-stimulating effects that make full hGH problematic for long-term use.
The hGH Fat-Burning Mechanism
Full human growth hormone stimulates lipolysis (fat breakdown) through activation of beta-3 adrenergic receptors and hormone-sensitive lipase in adipose tissue. The C-terminal fragment (hGH176-191) — which is AOD-9604 — contains the specific amino acid sequence responsible for this lipolytic activity, without the N-terminal sequences responsible for IGF-1 stimulation and insulin resistance.
Clinical Trial Results
Phase II trials demonstrated significant reductions in body fat, particularly visceral and abdominal fat, without effects on blood glucose, insulin sensitivity, or IGF-1 levels. This safety profile makes AOD-9604 suitable for longer-term use than full hGH, which cannot be used continuously without significant metabolic side effects.
Optimal Protocol
AOD-9604 works best in a fasted state — administered in the morning before eating, or before training. The peptide enhances the lipolytic response to exercise and fasting, making it most effective when combined with intermittent fasting and resistance training. Standard dose: 300mcg SubQ once daily. Cycle: 3 months on, 1 month off.